INTRODUCTION {#S1}
============

Although antiretroviral therapy (ART) has dramatically reduced morbidity and mortality for HIV-infected individuals, it does not eradicate HIV, leading to lifelong elevated immune activation and inflammation, ongoing damage to multiple organs systems, and reduction in life expectancy ([@R16]). The barrier to viral eradication during therapy is the ability of HIV to establish persistent infection mainly in CD4^+^ T cells and possibly in other cell types in blood, as well as both lymphoid and non-lymphoid sites ([@R12]; [@R17]; [@R19]; [@R73]). Most studies have characterized HIV latency in resting CD4^+^ T cells, which typically do not produce viral RNA or proteins (i.e., HIV-infected transcriptionally inactive cells) ([@R12]). However, a portion of the HIV reservoir *in vivo* resides in CD4^+^ T cells that maintain active HIV transcription, despite long-term ART (i.e., HIV-infected transcriptionally active cells) ([@R75]). The field lacks a detailed understanding of the phenotype of persistent HIV-infected cells, transcriptionally active and/or transcriptionally inactive, that can differentiate them from uninfected cells or from each other. Such a phenotype would enable a deeper understanding of the biology of HIV persistence. Here, we describe a glycomic feature of HIV-infected transcriptionally active cells that not only differentiates them from their transcriptionally inactive counterparts but also may affect their tissue trafficking abilities and therefore HIV persistence.

All living cells assemble a diverse repertoire of glycan structures on their surface via their glycosylation machinery ([@R71]). With recent advances in the fields of glycobiology and glycoimmunology ([@R14]), it has become clear that cell-surface glycosylation and glycan-lectin signaling play critical roles in regulating multiple cellular processes and immune functions ([@R2]), as well as cell-cell interactions ([@R15]) and cell-pathogen interactions ([@R13]; [@R18]; [@R23]). Altered glycan structures can serve as biomarkers for cancer and infectious diseases ([@R22]; [@R42]; [@R51]), and they have been used to design carbohydrate-based therapeutic vaccines ([@R32]). Furthermore, several viral infections (herpes simplex virus 1 \[HSV-1\], varicella-zoster virus \[VZV\], cytomegalovirus \[CMV\], and human T cell leukemia virus type 1 \[HTLV1\]) have been shown to alter cell-surface glycosylation in infected cells ([@R29]; [@R37]; [@R54], [@R55]). However, the relevance of the host glycosylation machinery to HIV persistence has never been explored.

We hypothesized that the cell surface of HIV-infected CD4^+^ T cells during ART has a distinct glycomic signature that can affect their function and/or fate. To address this, we performed a comprehensive glycomic analysis of the surface of cells isolated from a primary cell model of HIV latency. We found that the cell surface of HIV-infected transcriptionally active CD4^+^ T cells harbors high levels of fucosylated carbohydrate ligands compared with HIV-infected transcriptionally inactive cells. We confirmed these results using CD4^+^ T cells isolated directly from HIV-infected ART-suppressed individuals. We identified that the cell extravasation mediator Sialyl-Lewis^X^ (SLe^X^) is one of these enriched fucosylated carbohydrate ligands on the surface of HIV-infected transcriptionally active cells. We also found that active HIV transcription, but not cellular activation, induces SLe^X^ cell-surface expression *in vitro*. Finally, we performed a comprehensive phenotypic and transcriptomic analysis of CD4^+^ T cells expressing high levels of SLe^X^ isolated from HIV-infected ART-suppressed individuals. These analyses showed that cells with high-SLe^X^ (SLe^X-Hi^) are enriched with markers associated with HIV susceptibility, signaling pathways that drive HIV transcription, and pathways involved in leukocyte extravasation and T cell trafficking.

RESULTS {#S2}
=======

Distinct Glycomic Features of the CD4^+^ T Cell Surface Associate with Persistent HIV Transcription In Vitro {#S3}
------------------------------------------------------------------------------------------------------------

To examine whether CD4^+^ T cell-surface glycomic features associate with HIV persistence, we used a dual-fluorescent, reporter-based HIV (dfHIV) that incorporates two fluorescent proteins into the HIV genome: green fluorescent protein (GFP) for monitoring HIV promoter-dependent gene expression and blue fluorescent protein (BFP) under the control of a constitutive cellular promoter. dfHIV enables the differentiation and purification of primary CD4^+^ T cells into three populations: HIV-infected transcriptionally inactive (BFP+ GFP−) cells, HIV-infected transcriptionally active (BFP+ GFP+) cells, and uninfected (BFP− GFP−) cells ([@R3]; [@R8]; [@R10]). Primary CD4^+^ T cells were isolated from three HIV-negative donors, activated using αCD3/αCD28, infected with dfHIV by spinoculation, and sorted four days post-infection, yielding activated uninfected cells, infected transcriptionally inactive cells, and infected transcriptionally active cells ([Figure S1A](#SD1){ref-type="supplementary-material"}). As an additional control, we included a culture of non-activated CD4^+^ T cells from the same donors; this culture was treated identically except that PBS was added instead of αCD3/αCD28 activating beads ([Figure S1B](#SD1){ref-type="supplementary-material"}). We isolated cell membrane proteins from each of the four populations and performed a 45-plex lectin microarray ([Table S1](#SD1){ref-type="supplementary-material"}) to profile the cell-surface glycomic signature of each population. This lectin micro- array enables sensitive analysis of multiple glycan structures by employing a panel of immobilized lectins (glycan-binding proteins) with known glycan-binding specificity, resulting in a specific glycan signature for each sample ([@R27]; [@R64], [@R65]). Using this *in vitro* latency model as a screening tool, we found that the glycomic signature of HIV-infected transcriptionally inactive cells clustered distinctly ([Figures S1C](#SD1){ref-type="supplementary-material"} and [S1D](#SD1){ref-type="supplementary-material"}) from that of the other three populations; this difference resulted from the differential binding of a set of lectins ([Figure S1E](#SD1){ref-type="supplementary-material"}), including AOL (*Aspergillus oryzae* lectin, which binds total/α1--6 core fucose), UEA-I (*Ulex europaeus* I lectin, which binds α1--2 branched fucose), ABA (*Agaricus bisporus* agglutinin lectin, which binds Thomsen-Friedenreich \[TF\] antigen, Galβ1--3GalNAcα1), and MAL-I (*Maackia amurensis* I lectin, which binds Siaα2--3Gal (β−1,4) GlcNAc). Our *in vitro* screening indicates that the proteins on the surface of HIV-infected transcriptionally inactive cells may have lower levels of fucose and higher levels of TF antigen and sialic acid compared with proteins on the cell-surface of the other three populations. However, as with any HIV latency model, dfHIV has limitations and caveats, including potentially poor expression of the cellular promoter, the possibility of recombination between the two reporters during reverse transcription, and the lack of the *nef* gene that is replaced by GFP ([@R3]; [@R38]). These caveats and others limit the utility of dfHIV to a screening tool and necessitate the *in vivo* validation of some or all of our *in vitro* preliminary observations using cells directly isolated from HIV-infected individuals on suppressive ART.

Levels of Fucosylated Carbohydrate Ligands Associate with Persistent HIV Transcription In Vivo {#S4}
----------------------------------------------------------------------------------------------

To validate our preliminary *in vitro* observations, we next assessed whether differential glycosylation levels corresponded with different levels of persistent HIV transcription *in vivo*. We used fluorescently labeled versions of the lectins identified in [Figure S1E](#SD1){ref-type="supplementary-material"} (AOL, UEA-I, ABA, and MAL-I) to sort CD4^+^ T cells from HIV-infected ART-suppressed individuals into groups with low (lowest 5% binding), medium, or high (highest 5% binding) levels of each tested glycan. Consistent with our *in vitro* data, we found that cells with low cell-surface total/core fucose, i.e., fucose^low^ (lower binding to AOL), exhibited lower levels of cell-associated HIV RNA (total elongated transcripts; [@R75]) compared with total CD4^+^ T cells, suggesting that HIV-infected transcriptionally inactive cells *in vivo* might be depleted of cell-surface fucose. However, and unlike our *in vitro* data, in which levels of fucose were not different between activated-un-infected and activated-infected cells, we found that cells with high cell-surface total/core fucose, i.e., fucose^hi^ (higher binding to AOL), exhibited higher levels of cell-associated HIV RNA compared with total CD4^+^ T cells ([Figure 1A](#F1){ref-type="fig"}). Comparing fucose^hi^ cells to fucose^low^ cells, we found that fucose^hi^ cells exhibited higher levels of cell-associated HIV RNA than did fucose^low^ cells (average of 17.2-fold enrichment of cell-associated HIV RNA in fucose^hi^ cells compared with fucose^low^ cells) despite less drastic differences in levels of HIV DNA (average of a 6.0-fold difference of HIV DNA) ([Figure 1A](#F1){ref-type="fig"}). Furthermore, the ratio between cell-associated HIV RNA and HIV DNA (a potential marker of HIV transcriptional activity) was higher in fucose^hi^ cells (average 51.2, median 41.5) than in fucose^low^ cells (average 20, median 6.5) ([Figure 1A](#F1){ref-type="fig"}).

Next, we examined binding to UEA-I (lectin that binds to branched fucose). We found that cells with high cell-surface branched fucose exhibited higher cell-associated HIV RNA compared with cells with low branched fucose (average of 8.2-fold enrichment) despite little difference in HIV DNA levels (average of 3.0-fold enrichment), but no significant difference in the ratio between cell-associated HIV RNA and HIV DNA was observed ([Figure 1B](#F1){ref-type="fig"}). However, unlike our *in vitro* data, we did not observe any difference in cell-associated HIV RNA levels, DNA levels, or the ratio between HIV RNA and DNA in cells binding to MAL-I (Siaα2--3Gal (β−1,4) GlcNAc) or ABA lectin (TF antigen) ([Figures S2A](#SD1){ref-type="supplementary-material"} and [S2B](#SD1){ref-type="supplementary-material"}). The data in [Figures 1A](#F1){ref-type="fig"} and [1B](#F1){ref-type="fig"} suggest that altered T cell-surface fucosylation patterns associate with persistent HIV transcriptional activity *in vivo*: low cell-surface fucosylation is associated with transcriptional-inactive HIV during ART, whereas high cell-surface fucosylation is associated with transcriptional-active HIV during ART.

Surface Expression of the Fucosylated Glycoantigen SLe^X^ on CD4^+^ T Cells Associates with HIV Transcription In Vivo {#S5}
---------------------------------------------------------------------------------------------------------------------

The oligosaccharide SLe^X^ is a fucosylated carbohydrate that binds the selectin family of lectins and mediates many important cell-cell processes, including extravasation. Given our finding that total fucosylated glycans are enriched on the surface of HIV-infected transcriptionally active cells ([Figures 1A](#F1){ref-type="fig"} and [1B](#F1){ref-type="fig"}), we hypothesized that the fucosylated glycoantigen SLe^X^ may be one of the fucosylated antigens enriched on these cells. SLe^X^ is usually attached to *O*-glycans and exists in two forms: (1) a non-sulfated form simply called SLe^X^ and (2) a sulfated form called CLA (cutaneous lymphocyte antigen). We used antibodies specific for SLe^X^ or CLA to sort CD4^+^ T cells from HIV-infected ART-suppressed individuals. We found that cells with high cell-surface levels of SLe^X^ had increased cell-associated HIV RNA levels compared with cells with low-SLe^X^ (SLe^X-Low^) expression (4.9-fold difference for cell-associated HIV RNA) despite similar levels of HIV DNA (0.9-fold difference) ([Figure 1C](#F1){ref-type="fig"}). The ratio between cell-associated HIV RNA and HIV DNA was higher in SLe^X-Hi^ cells (average 88.0, median 46.6) compared with SLe^X-Low^ cells (average 20.2, median 21.0) ([Figure 1C](#F1){ref-type="fig"}). Similar, albeit weaker, results were observed for cells sorted using antibodies for CLA ([Figure 1D](#F1){ref-type="fig"}). To ensure that our observations were not the result of possible latent reactivation induced by these lectins/antibodies, we treated CD4^+^ T cells isolated from HIV-infected ART-suppressed individuals with AOL, UEA-I, SLe^X^, or CLA antibodies for the same duration required to perform cell sorting (3 h). This treatment did not reactivate latent infection or induce cell-associated HIV RNA expression ([Figure S2C](#SD1){ref-type="supplementary-material"}). Altogether, these data suggest that high levels of the fucosylated glycomic antigen SLe^X^ on the CD4^+^ T cell-surface associate with persistent HIV transcription *in vivo*.

We also compared levels of SLe^X^ and CLA on CD4^+^ T cells (total and memory) of HIV-infected (ART-suppressed and viremic) and HIV-negative controls. We found higher frequencies of SLe^X+^ cells on total CD4^+^ T cells of viremic (median 35%, inter-quartile range \[IQR\] 11.2) and ART-suppressed (median 26.8%, IQR 5.4) individuals compared with HIV-negative controls (median 15.3%, IQR 2.1). Similarly, we found a larger proportion of SLe^X+^ cells on memory CD4^+^ T cells of viremic (median 29.7%, IQR 11.4) and ART-suppressed (median 22.6%, IQR 8.9) individuals compared with HIV-negative controls (median 15.5%, IQR 4.5) ([Figure 1E](#F1){ref-type="fig"}). We also found a higher frequency of cells expressing CLA on total CD4^+^ T cells of viremic (median 71%, IQR 14.2) and ART-suppressed (median 58.3%, IQR 4.4) individuals compared with HIV-negative controls (median 41.2%, IQR 6.2). A larger proportion of memory CD4^+^ T cells similarly expressed higher levels of CLA^high^ in viremic (median 32%, IQR 10.2) and ART-suppressed (median 26.3%, IQR 5.4) individuals compared with HIV-negative controls (median 17.6%, IQR 3) ([Figure 1F](#F1){ref-type="fig"}). We also found that levels of SLe^X+^ and CLA^+^ CD4^+^ T cells correlate with viral load in HIV-infected individuals ([Figure S2D](#SD1){ref-type="supplementary-material"}). These results indicate that high cell-surface expression of SLe^X^ is associated with HIV infection, irrespective of viral suppression by ART.

HIV Infection, but Not Cellular Activation, Induces the Expression of SLe^X^ and CLA on the Surface of Primary CD4^+^ T Cells {#S6}
-----------------------------------------------------------------------------------------------------------------------------

To investigate whether HIV infection or cellular activation directly induces SLe^X^ expression, we first infected primary unstimulated CD4^+^ T cells from three HIV-uninfected donors with either an X4 virus (IIIB) or a dual-tropic virus (89.6). Four days later, we assessed HIV infection rates and SLe^X^ or CLA cell-surface expression levels by flow cytometry. HIV p24^+^ cells exhibited a higher percentage of SLe^X^ and CLA compared with uninfected control ([Figures S3A](#SD1){ref-type="supplementary-material"}--[S3D](#SD1){ref-type="supplementary-material"}). However, given the low levels of infection resulting from infecting CD4^+^ T cells with HIV without prior activation, we did not observe an induction of the total percentage of SLe^X+^ or CLA^+^ CD4^+^ T cells upon infection in this experiment. Therefore, there are two potential explanations for these results: (1) HIV infection induces the expression of SLe^X^ and CLA on the surface of infected cells, or (2) cells expressing these markers are preferentially infected with HIV.

To test whether the first possibility is occurring, i.e., that HIV infection can directly induce the expression of SLe^X^ and/or CLA, we used CD44 MicroBeads to enhance HIV infection of unstimulated CD4^+^ T cells ([@R67]). Consistent with [@R67], CD44 MicroBeads dramatically enhanced HIV replication in unstimulated CD4^+^ T cells with minimal impact on T cell activation ([Figure S3E](#SD1){ref-type="supplementary-material"}). Infecting primary CD4^+^ T cells with 89.6 virus or DH12 virus (a dual-tropic virus), in the presence of CD44 MicroBeads, resulted in a significant induction of the total percentage of SLe^X+^ CD4^+^ T cells compared with CD4^+^ T cells treated with CD44 MicroBeads alone ([Figure 2A](#F2){ref-type="fig"}). This induction was driven by HIV p24^+^ cells ([Figure 2A](#F2){ref-type="fig"}). Next, we examined the impact of HIV infection on CLA expression. Given the high background of CLA on primary CD4^+^ T cells ([Figure S3D](#SD1){ref-type="supplementary-material"}), we first depleted CLA^+^ CD4^+^ T cells using rat anti-human CLA antibody coupled with anti-rat kappa MicroBeads to remove background and improve the chance of observing an increase in the total percentage of CLA^+^ CD4^+^ T cells upon infection ([Figure S3F](#SD1){ref-type="supplementary-material"} shows the successful depletion of CLA from the surface of primary CD4^+^ T cells). Infecting CLA-depleted primary CD4^+^ T cells with 89.6 or DH12 viruses, in the presence of CD44 MicroBeads, resulted in a significant induction of the total percentage of CLA^+^ CD4^+^ T cells compared with CD4^+^ T cells treated with the CD44 MicroBeads alone ([Figure 2B](#F2){ref-type="fig"}). This induction was significantly more pronounced in HIV p24^+^ cells than in p24^−^ cells ([Figure 2B](#F2){ref-type="fig"}). Potential explanations for the induction of CLA in p24^−^ cells are that some of these cells are infected but with insufficient p24 expression to be detected by flow cytometry or that there is transcellular transactivation by viral proteins. Importantly, infection with heat-inactivated virus was unable to induce CLA, suggesting that active viral replication is needed for HIV-mediated CLA induction ([Figure S3G](#SD1){ref-type="supplementary-material"}).

To examine whether HIV infection induces the expression of glycosyltransferases (enzymes that catalyze glycosidic bond formation) involved in the production of SLe^X^ and CLA, we infected H9 cells (HIV-susceptible human CD4^+^ T cell line) with either 89.6 or NL4--3 viruses and examined the protein expression of some of these glycosyltransferases ([Figure 2C](#F2){ref-type="fig"}). In particular, we exam ined the protein expression of FUT7 and FUT6 (α-(1,3)-fucosyltransferases), enzymes that add α-(1,3)-fucose to the SLe^X^ or CLA carbohydrate structures, and B4GALT5, (β−1,4-galactosyltransferase 5), an enzyme that adds galactose into the *O*-glycan backbone of SLe^X^ and CLA ([Figure 2C](#F2){ref-type="fig"}). We also tested for HIV p24 protein expression as a marker of successful HIV infection. As shown in [Figure 2C](#F2){ref-type="fig"}, HIV infection induced the protein expression of these glycosyltransferases involved in SLe^X^ and CLA production. Altogether, these results demonstrate that HIV infection can directly induce the expression of SLe^X^ and CLA on primary CD4^+^ T cells; however, it does not exclude the additional possibility that cells constitutively expressing these markers are preferentially infected with HIV.

We also activated primary CD4^+^ T cells from three HIV-uninfected donors with five activating agents (αCD3/αCD28, tumor necrosis factor alpha \[TNF-α\], interleukin-2 \[IL-2\], IL-2+αCD3/αCD28, or IL-2+TNF-α) for four days and measured SLe^X^ and CLA expression. As shown in [Figure S6H](#SD1){ref-type="supplementary-material"}, we did not observe induction of SLe^X^ or CLA under these activation conditions. These results suggest that HIV infection directly induces the cell-surface expression of SLe^X^ and CLA but cellular activation (using the aforementioned conditions) does not.

SLe^X^ Expression Is Enriched on Central Memory and Naive CD4^+^ T Cells and Associates with Higher Activation Status {#S7}
---------------------------------------------------------------------------------------------------------------------

To examine the composition and distribution of SLe^X^ expression in CD4^+^ T cell subsets, T cells were obtained from peripheral blood mononuclear cell (PBMC) samples of uninfected, ART-suppressed, and viremic HIV-infected donors. Flow cytometry gating strategies used for identifying the CD4^+^ T cell subsets and SLe^X^ expression and representative examples are shown in [Figure S4A](#SD1){ref-type="supplementary-material"}. We found that the T cell memory subset distribution within SLe^X+^-expressing cells was similar between HIV-negative and HIV-infected individuals, and most SLe^X+^ cells had either a naive or a central memory T cell (T~CM~) phenotype ([Figure 3A](#F3){ref-type="fig"}). Naive, stem memory T cells (T~SCM~), T~CM~, and transitional memory T cells (T~TM~) from ART-suppressed individuals had higher frequencies of SLe^X+^ cells compared with their counterparts from HIV-negative controls ([Figure 3B](#F3){ref-type="fig"}). All CD4^+^ T cell subsets exhibit elevated SLe^X^ in viremic individuals ([Figure 3B](#F3){ref-type="fig"}). We also examined the expression of 17 cell-surface markers measured on SLe^X+^ and SLe^X−^ CD4^+^ T cells and found that SLe^X+^ CD4^+^ T cells from HIV-infected ART-suppressed individuals had higher proportions of the HIV co-receptors CCR5 and CXCR4, as well as CCR7, CD25, CD27, CD38, CD45RA, CD127, FoxP3, and Ki-67. In contrast, the levels of CD95 were lower in SLe^X+^ compared with SLe^X−^ CD4^+^ T cells ([Figure 3C](#F3){ref-type="fig"}; [Figure S5](#SD1){ref-type="supplementary-material"}). Using these markers, we identified the T helper (Th) phenotype of SLe^X+^ CD4^+^ T cells. We analyzed the frequency of circulating follicular T cells (\[cTfhs\] CXCR5^+^ PD1^+^), regulatory T cells (\[Tregs\] non-cTfhs CD127^lo/−^ CD25^+^ FoxP3^+^), Th1 (non-cTfhs/non-Tregs CXCR3^+^ CCR4^−^ CCR6^−^), Th2 (non-cTfhs/non-Tregs CXCR3^−^ CCR4^+^ CCR6^−^), Th17 (non-cTfhs/non-Tregs CXCR3^−^ CCR4^+^ CCR6^+^), and Th17+1 (non-cTfhs/non-Tregs CXCR3^+^ CCR4^−^ CCR6^+^) within these cells ([Figure S6A](#SD1){ref-type="supplementary-material"}). We found that SLe^X+^ CD4^+^ T cells are mainly of the Th2, Th17, and CXCR5^+^ non-cTfh phenotypes, irrespective of HIV/ART status ([Figure S6B](#SD1){ref-type="supplementary-material"}). We also found that the frequency of cTfhs, CXCR5^+^, Th17 cells, and Th2 cells expressing SLe^X+^ was higher in viremic individuals compared with HIV-negative controls. Furthermore, the frequency of CXCR5+ non-cTfhs, Th17 cells, and Th2 cells expressing SLe^X+^ was higher in ART-suppressed individuals compared with HIV-negative controls ([Figure S6C](#SD1){ref-type="supplementary-material"}). Altogether, these data show that most SLe^X+^ CD4^+^ T cells are of the naive and T~CM~ phenotypes, express markers associated with HIV susceptibility, and express one or more activation markers.

CLA^high^ CD4^+^ T Cells Cluster Distinctly from CLA^low^ and CLA^negative^ CD4^+^ T Cells {#S8}
------------------------------------------------------------------------------------------

Next, we examined the composition and distribution of CLA^+^ cells within CD4^+^ T cell subpopulations. Flow cytometry gating strategies used for identifying CD4^+^ T cell subsets, and representative examples of CLA expression are shown in [Figure S4B](#SD1){ref-type="supplementary-material"}. We performed unbiased clustering and principal-component analyses (PCAs) using the expression of 17 cell-surface markers measured on CLA^high^, CLA^low^, and CLA^negative^ CD4^+^ T cells ([Figure 4A](#F4){ref-type="fig"}). These analyses showed that CLA^high^ cells have a phenotype distinct from CLA^low^ and CLA^negative^ CD4^+^ T cells, and this phenotype is similar between viremic and aviremic HIV-infected individuals ([Figure 4A](#F4){ref-type="fig"}). Of note, HIV and ART status did not cluster separately across CLA^negative^, CLA^low^, and CLA^high^ subpopulations. We found that CLA^high^ cells have almost exclusively a T~CM~ phenotype ([Figure 4B](#F4){ref-type="fig"}). We also found that their frequency is elevated in HIV-infected individuals regardless of treatment status ([Figure 4C](#F4){ref-type="fig"}) and that they are enriched with HIV co-receptors and activation markers ([Figure 4D](#F4){ref-type="fig"}). Focusing on Th phenotypes, we found that CLA^high^ CD4^+^ T cells are mainly of Th2 and Th17 phenotypes, irrespective of HIV/ART status ([Figure S6C](#SD1){ref-type="supplementary-material"}). We also found that the frequency of cTfhs, Tregs, CXCR5^+^, Th1, and Th17 cells expressing CLA^high^ was higher in viremic individuals compared with HIV-negative controls. Furthermore, the frequency of CXCR5^+^ non-cTfhs and Th17+1 cells expressing CLA^high^ was higher in ART-suppressed individuals compared with HIV-negative controls ([Figure S6D](#SD1){ref-type="supplementary-material"}). Altogether, these data show that CLA^high^ CD4^+^ T cells have a T~CM~ phenotype and exhibit a distinct phenotype compared with CLA^low^ and CLA^negative^ CD4^+^ T cells.

SLe^X+^ CD4^+^ T Cells Are Enriched with Several Host Proteins Known to Be Associated with HIV Persistence during ART {#S9}
---------------------------------------------------------------------------------------------------------------------

Some persistence-associated host proteins are enriched in HIV-infected cells during ART, including PD-1, TIGIT, CTLA-4, CCR6, Survivin, and CD30 ([@R21]; [@R24]; [@R31]; [@R41]; [@R50]). The expression patterns of these factors in the context of transcriptionally active versus transcriptionally inactive cells are not clear, except for CD30, which is known to be enriched on the surface of cells actively transcribing HIV ([@R31]). We examined the relationship between SLe^X^ expression and PD-1, TIGIT, CTLA-4, CCR6, CD30, and Survivin expression on freshly isolated peripheral blood CD4^+^ T cells from nine HIV-infected ART-suppressed individuals by CyTOF (cytometry by time of flight). We found that relative to SLe^X−^ cells, SLe^X+^ cells were enriched for cells expressing PD-1, TIGIT, CTLA-4, CCR6, and CD30. In comparison, SLe^X−^ cells are enriched for cells expressing Survivin ([Figure 5A](#F5){ref-type="fig"}). Consistently, CD4^+^ T cells expressing high levels of PD-1, TIGIT, CTLA-4, CCR6, and CD30 express higher levels of SLe^X^ compared with cells that do not express these markers. In contrast, Survivin^+^ cells express low levels of SLe^X^ compared with survivin^−^ cells ([Figure 5B](#F5){ref-type="fig"}). These results suggest that SLe^X^ expression is associated with the expression of several putative markers of HIV persistence on the surface of CD4^+^ T cells during suppressive ART.

SLe^X+^ CD4^+^ T Cells Are Enriched for Pathways Involved in T Cell Extravasation and HIV Transcription {#S10}
-------------------------------------------------------------------------------------------------------

Using RNA sequencing (RNA-seq), we characterized the transcriptomes of SLe^X-Hi^ and SLe^X-Low^ CD4^+^ T cells isolated from four HIV-infected ART-suppressed individuals. We first examined the gene expression patterns of some glycosyltransferases involved in the synthesis of mature, core 2 *O*-glycans bearing SLe^X^. As expected, SLe^X-Hi^ cells express high levels of GCNT1 (β−1,3-galactosyl-O-glycosyl-glycoprotein β−1,6-N-acetylgluco saminyltransferase) and FUT7 ([Figure 6A](#F6){ref-type="fig"}). GCNT1 is a core 2 *O*-glycan initiation enzyme essential to the formation of Gal β1--3(GlcNAc β1--6)GalNAc structures and the core 2 *O*-glycan branch. These data confirm that SLe^X^ is enriched on the sorted populations used in the RNA-seq experiments.

Overall, we found 1,086 genes significantly differentially expressed (false discovery rate \[FDR\] \< 5%, at least 2-fold) between SLe^X-Hi^ and SLe^X-Low^ CD4^+^ T cells. We used Ingenuity Pathway Analysis (IPA) to evaluate the functional significance of the genes. IPA identified clear enrichment of pathways and functions ([Figures 6B](#F6){ref-type="fig"}--[6D](#F6){ref-type="fig"}) associated with higher leukocyte migration and extravasation in SLe^X-Hi^ (cells harboring more transcriptionally active HIV) compared with SLe^X-Low^ cells (cells harboring more transcriptionally inactive HIV). We found that two signaling pathways known to drive HIV transcription were enriched in SLe^X-Hi^ versus SLe^X-Low^ CD4^+^ T cells. These signaling pathways are nuclear factor κB (NF-κB) ([@R9]; [@R49]) and NFAT ([@R6]; [@R49]) ([Figures 6B](#F6){ref-type="fig"}, [6C](#F6){ref-type="fig"}, and [6E](#F6){ref-type="fig"}). These data suggest that the NF-κB and/or NFAT signaling pathways may underlie the higher persistent HIV transcription in SLe^X-Hi^ compared with SLe^X-Low^ cells.

DISCUSSION {#S11}
==========

In this study, we examined the relationship between cell-surface glycosylation patterns of HIV-infected cells and persistent HIV transcription. We identified fucosylated carbohydrates to be enriched on the surface of HIV-infected transcriptionally active cells despite ART suppression. Conversely, the levels of these fucosylated carbohydrates are low on the surface of HIV-infected transcriptionally inactive cells. This glycomic feature of HIV-infected cells actively producing HIV transcripts is possibly a product of viral transcription and potentially has a phenotype significance on the trafficking abilities of these cells. In particular, the cell extravasation mediator SLe^X^ is one of the fucosylated carbohydrate ligands enriched on the surface of HIV-infected transcriptionally active cells and reduced on the surface of HIV-infected transcriptionally inactive cells. This observation would suggest potential differential trafficking abilities of these cells. Such differential abilities might affect maintenance of HIV persistence and should be considered when targeting HIV reservoirs in blood and tissues.

Identifying host factors enriched in HIV-infected cells (both latent and actively transcribing) during ART could provide the HIV cure field with vital biological clues into the molecular pathways involved in viral persistence. These host factors may be different between HIV-infected transcriptionally active and HIV-infected transcriptionally inactive cells. For example, it has been observed that persistent HIV proviruses are enriched in several memory CD4^+^ T cell compartments ([@R11]). Some host factors are also enriched in HIV-infected cells (transcriptionally active or not) during long-term ART. These factors include the immune negative checkpoints PD-1, TIGIT, LAG-3 ([@R21]), and CTLA-4 ([@R50]), as well as other factors such as CD2 ([@R33]), CCR6 ([@R24]), and Survivin ([@R41]). Other host factors are shown to be enriched, in particular, in HIV-infected transcriptionally active cells, such as CD30 ([@R31]) and CD20 ([@R61]). These factors, especially those that reside on the cell surface, may be useful for targeting these cells and can provide a better understanding of HIV persistence biology.

Recent advances in the cancer field demonstrated that the aberrant glycosylation pattern of cancer cells alters their functions and interaction with the immune system ([@R58]; [@R60]). Such advances have promoted increasing interest in developing novel tools to target the tumor glycocode ([@R60]). However, the relevance of the host glycosylation machinery to HIV persistence has not been evaluated previously. We found that cell-surface fucosylation is enriched on the surface of HIV-infected transcriptionally active cells and is reduced on the surface of HIV-infected transcriptionally inactive cells *in vitro*. Future studies will be needed to identify the potential additive enrichment of persistent HIV-infected cells when combining cell-surface fucosylation with other host factors, mentioned earlier, that are enriched on HIV-infected cells during ART. Most proviruses persisting in HIV-infected ART-treated individuals harbor mutations and/or deletions, rendering them defective ([@R7]; [@R30]). However, not all intact viruses are inducible, and both intact and defective proviruses can express viral RNA and proteins ([@R34]; [@R59]). It is possible that cells with high cell-surface fucose in general (and SLe^X^ in particular) are enriched with intact HIV genomes compared with cells with low cell-surface fucose, given the higher HIV transcriptional ac tivity of these former cells. However, this possibility will need to be investigated using single-genome, near-full-length proviral sequencing to determine the genetic makeup of the virus infecting cells with differential levels of fucosylation.

Many T cell processes and functions are shaped by cell-surface glycosylation ([@R57]). For example, T cell-surface fucosylation is critical for T cell activation via T cell receptor (TCR) signaling ([@R46]), and the fucosylation of T cell immune negative checkpoints (such as PD-1) is critical for their function ([@R56]). It is unclear how these two published observations may contribute to our findings. Among the total fucosylated carbohydrate ligands, we found that SLe^X^, which has important implications for T cell trafficking, is enriched on the surface of HIV-infected transcriptionally active cells. However, this 5-fold enrichment is significantly lower than the enrichment of total/core fucose (17-fold) found when using AOL (which binds total/core fucose). These results suggest that other fucosylated ligands may be enriched on the surface of HIV-infected transcriptionally active cells and depleted on the surface of HIV-infected transcriptionally inactive cells. Identifying these other glycan structures and their exact protein and lipid backbones should be the subject of future studies and will likely allow us a better understanding of the role of cell-surface fucosylation in modulating T cell functions and HIV persistence. Further studies will also be needed to examine the potential biological significance of this altered fucosylation on HIV-infected T cell biology and function.

The process of leukocyte extravasation is well described and requires binding of selectins (a type of lectins) to fucosylated carbohydrates. T cells exit the vasculature to reach their target tissue through the leukocyte adhesion cascade, a coordinated series of events involving (1) selectin-mediated rolling, (2) chemokine-triggered activation, and (3) integrin-dependent arrest ([@R44]). Selectins are a family of receptors comprising platelet (P), endothelial (E), and leukocyte (L) selectin. To mediate rolling, selectins bind with their fucosylated carbohydrate ligands, notably SLe^X^ ([@R35]). Upon antigen stimulation, some T cells become activated and induce cell-surface expression of SLe^X^; SLe^X^ binding to P- and E-selectin on vascular endothelium regulates the trafficking of these T cells into various non-lymphoid tissues. Some of these T cells can traffic back to the lymph nodes through the lymph ([@R25]; [@R72]; [@R74]). Our transcriptomic analysis demonstrated enrichment of T cell extravasation and trafficking pathways in CD4^+^ T cells with high levels of SLe^X^ compared with cells with low levels of SLe^X^. These data suggest that HIV-infected transcriptionally active CD4^+^ T cells may have higher trafficking abilities compared with HIV-infected transcriptionally inactive CD4^+^ T cells. These differential characteristics of HIV-infected T cells trafficking to lymphoid and non-lymphoid tissues in their HIV transcriptional activity and cell-surface glycomic features could be considered for targeting the tissue-based HIV reservoir. Selectin antagonists such as bimosiamose ([@R20]; [@R39]; [@R48]) and rivipansel ([@R66]) have been used in humans and could be explored in the context of HIV infection to temporarily trap HIV-infected cells in blood for immunotherapeutic clearance.

Our data suggest that HIV infection can directly induce the expression of SLe^X^ on the surface of CD4^+^ T cells. The mechanism that underlies this induction is not clear. Different viral infections have been described to induce the cell-surface expression of fucosylated carbohydrate ligands, including HSV-1, VZV, and CMV ([@R54], [@R55]). HTLV1 infection has been shown to induce SLe^X^ through the viral transactivator *Tax* ([@R29]; [@R37]; [@R70]). Future studies will be needed to investigate the possibility that HIV induces SLe^X^ through its viral transactivator *Tat*. However, infection cannot explain the entirety of the difference we found in the levels of SLe^X^ on the surface of CD4^+^ T cells from viremic and ART-suppressed HIV-infected individuals, because not all T cells from HIV-infected individuals are infected. There are two possibilities: (1) Although our data show that activation using αCD3/αCD28, TNF-α, or IL-2 does not induce the expression of SLe^X^, we cannot exclude the possibility that stimulation using other stimulants, *in vivo*, would induce SLe^X^ expression. (2) Viral proteins (including *tat* and *nef*) can exist in circulation (especially in exosomes) and can be taken by uninfected cells and affect them. HTLV-1 *Tax* significantly enhances the ability of cell activation to induce FUT7 ([@R28]). Therefore, although our data show that active HIV infection can directly induce SLe^X^, likely other factors synergize with HIV infection, leading to this enrichment *in vivo*. Although our data show that HIV infection can directly induce the expression of SLe^X^, it does not exclude the possibility that cells are preferentially infected with HIV. This latter possibility is supported by our observation that cells expressing SLe^X^ are enriched with HIV co-receptors and activation markers. Future studies will be needed to determine the contribution of (1) the direct impact of HIV transcription on SLe^X^ expression and (2) the impact of cellular susceptibility to infection on our observed enrichment of SLe^X^ on the surface of HIV-infected transcriptionally active cells during ART. In addition, several cancers have higher levels of fucose in general ([@R1]; [@R5]), and SLe^X^ in particular ([@R36]; [@R53]; [@R68]), that affect their functions and contribute to their metastasis (through binding to selectins). Therefore, several mechanisms clearly contribute to SLe^X^ induction. Understanding the upstream modulator or modulators of fucose and SLe^X^ enrichment on HIV-infected transcriptionally active cells, as well as the downstream consequences of this enrichment, should be the subject of future studies to better understand HIV persistence.

Our study provides the first insight into a potential role of circulating CD4^+^ T cell-surface glycome in persistent HIV transcription activity. However, our findings have limitations, including the following: (1) Our data were obtained from blood; there is a need to analyze the potential enrichment of fucosylated glycans, including SLe^X^, in tissues such as lymph nodes and gut-associated lymphoid tissues. (2) Our *in vivo* phenotyping analysis was done mainly on cryopreserved PBMCs, and it is possible that freezing/thawing affects these phenotypes. (3) Our data were obtained using cross-sectional samples from chronically infected adults; there will be a need to analyze longitudinal changes, acute infection, and samples from geographically and/or age-distributed cohorts. (4) We did not comprehensively validate *in vivo* all glycomic signatures of HIV-infected cells identified in *in vitro*. Future studies will need to examine whether additional glycomic signatures of HIV-infected cells can be confirmed *in vivo* or identified *in vitro* (using other HIV latency models and/or other glycomic technologies such as mass spectrophotometry). That said, we think our study is an important step toward elucidating the potential glycomic underpinnings of HIV persistence. In summary, we identified fucosylation to be a feature of persistent HIV transcriptional activity *in vivo*. The role of cell-surface fucosylation (including SLe^X^ expression) in HIV persistence warrants further investigation to better understand persistent HIV expression during ART and identify glycan-based interactions that can be targeted for novel HIV immunotherapies.
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RESOURCE AVAILABILITY {#S13}
---------------------

### Lead Contact {#S14}

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Mohamed Abdel-Mohsen (<mmohsen@wistar.org>).

### Materials Availability {#S15}

This study did not generate new unique reagents.

### Data and Code Availability {#S16}

The RNA-seq data were submitted to GEO (<https://www.ncbi.nlm.nih.gov/geo/>) under accession number GSE151453

EXPERIMENTAL MODEL AND SUBJECT DETAILS {#S17}
--------------------------------------

### Cell lines {#S18}

ACH-2, H9, and TZM-bl cells were maintained at 37°C in RPMI 1640 medium supplemented with 10% FBS, L-glutamine (2 mM), penicillin (50 U/ml), and streptomycin (50 mg/ml).

### Human primary CD4^+^ T Cell {#S19}

We used CD4^+^ T cells isolated from the peripheral blood mononuclear cell (PBMC) of 11 HIV-infected ART-suppressed individuals for the sorting experiments in [Figures 1A](#F1){ref-type="fig"}--[1D](#F1){ref-type="fig"} ([Table S2](#SD1){ref-type="supplementary-material"}). Frozen PBMCs of these individuals were obtained from 1) the External Quality Assurance Program Oversight Laboratory (EQAPOL), located at the Duke Human Vaccine Institute's Immunology and Virology Quality; and 2) The Wistar Institute and the Philadelphia FIGHT cohort. Frozen PBMCs from HIV-negative, HIV-infected ART-suppressed, and HIV-infected viremic individuals were used for the flow cytometry profiling experiments in [Figures 1E](#F1){ref-type="fig"}, [1F](#F1){ref-type="fig"}, [3](#F3){ref-type="fig"}, and 4 ([Table S3](#SD1){ref-type="supplementary-material"}). PBMCs from HIV-infected viremic and ART-treated individuals were obtained from INER-CIENI (Mexico). Healthy HIV-negative PBMC samples were obtained from the University of Pennsylvania Human Immunology Core. We used freshly isolated CD4^+^ T cells from the PBMC of nine HIV-infected ART-suppressed individuals for the CyTOF experiments in [Figure 5](#F5){ref-type="fig"} ([Table S4](#SD1){ref-type="supplementary-material"}). PBMCs of these individuals were obtained from The Wistar Institute and the Philadelphia FIGHT cohort. Research protocols were approved by Duke University, The Wistar Institute, Philadelphia FIGHT, and the University of Pennsylvania Committees on Human Research. Written informed consent was obtained, and all data and specimens were coded to protect confidentiality.

METHOD DETAILS {#S20}
--------------

### Primary CD4^+^ T cells infection with the dual fluorescent reporter-based HIV (dfHIV) {#S21}

Primary CD4^+^ T cells were isolated from the PBMCs of three HIV-uninfected donors using the Human EasySep Human CD4+ T Cell Isolation Kit (StemCell Technologies, cat\# 17952). Purified CD4^+^ T cells were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS), L-glutamine (2 mM), penicillin (50 U/ml), and streptomycin (50 mg/ml). Purified CD4^+^ T cells were stimulated with αCD3/αCD28 activating beads (Life Technologies, cat 11131D) at a concentration of 1 bead/cell in the presence of 30 U/ml IL-2 (PeproTech, cat\# 200--20) for three days. Non-Activated CD4^+^ T cells from the same donors were included as controls; this culture was treated identically except PBS was added instead of activating beads. Cells were then spinoculated with either PBS or dfHIV (generously provided to us by Dr. Leonard Chavez at Vitalant Research Institute) ([@R3]; [@R8]; [@R10]), at a concentration of 100 ng of p24 per 1 × 10^6^ cells for 2 h at 1,200 × g at 37°C. After spinoculation, all cells were returned to culture in the presence of 30 U/ml IL-2. Cells were sorted four days post-infection based on GFP and BFP fluorescence using BD FACSAria II (BD Biosciences). Cell-surface molecules from at least 100,000 sorted cells of each of the four populations were purified and labeled using ProteoExtract Subcellular Proteome Extraction Kit (Merck, cat\# 539790).

### Glycomic analysis using lectin microarrays {#S22}

A lectin microarray platform was used to profile 45 different glycan structures on the surface of sorted cells ([@R26], [@R27]; [@R52]; [@R62], [@R63], [@R64], [@R65]; [@R69]). The lectin array employs a representative panel of immobilized lectins with known glycan structure binding specificity. Cell-membrane proteins were labeled with Cy3 dye (GE Healthcare, cat\# GEPA23001) and hybridized to the lectin microarray. The resulting lectin chips were scanned for fluorescence intensity on each lectin-coated spot using an evanescent-field fluorescence scanner (GlycoTechnica Ltd.). All samples were run in triplicate, and the average of the triplicate was used for analysis. Data were normalized using the global normalization method.

### Sorting primary CD4^+^ T cells based on their binding to AOL lectin, UEAI lectin, SLe^X^ antibody, or CLA antibody {#S23}

Primary CD4^+^ T cells were negatively isolated from PBMCs of HIV-infected ART-suppressed individuals using the Human EasySep Human CD4^+^ T Cell Isolation Kit (StemCell Technologies, cat\#17952). Cells were stained with AOL-biotin conjugated (TCI America, cat\# A26591ML) followed with Streptavidin-APC (Biolegend, cat\# 405207), UEA-I FITC (Vector labs, cat\# FL-1061--2), SLe^X^ (CSLEX1, AF647; BD biosciences, cat\# 563526), or CLA (HECA-452, AF647; Biolegend, cat\# 321309). Cells were then sorted using the MoFlo Astrios EQ, Cell Sorter (Beckman Coulter) into cells with the lowest 5% binding, highest 5% binding, and rest of the cells.

### Cellular DNA and RNA extraction {#S24}

Sorted cells were lysed in RLT Plus Buffer (Allprep isolation kit, QIAGEN, cat\# 80224). Total DNA and total RNA were extracted simultaneously from the lysates using the Allprep DNA/RNA/miRNA Universal Kit (QIAGEN, cat\# 80224) with on-column DNase treatment (QIAGEN, cat\# 79254). RNA samples were quantified using Qubit 2.0 Fluorometer (Life Technologies), and RNA integrity was checked with 2100 Bioanalyzer (Agilent Technologies).

### qPCR quantification of HIV DNA and cell-associated HIV RNA {#S25}

Total HIV DNA and cell-associated HIV RNA were quantified with a qPCR TaqMan assay using LTR-specific primers F522--43 (5^′^ GCC TCA ATA AAG CTT GCC TTG A 3^′^; HXB2522--543) and R626--43 (5^′^ GGG CGC CAC TGC TAG AGA 3^′^; 626--643) coupled with a FAMBQ probe (5^′^ CCA GAG TCA CAC AAC AGA CGG GCA CA 3) ([@R40]) using the QuantStudio 6 Flex Real-Time PCR System (Applied Biosystems). Cell-associated HIV DNA copy number was determined using a reaction volume of 20 μL with 10 μL of 2x TaqMan Universal Master Mix II, including UNG (Applied Biosystems, cat\# 4440038), 4 pmol of each primer, 4 pmol of probe, and 5 μL of DNA. Cycling conditions were 50°C for 2 min, 95°C for 10 min, followed by 60 cycles of 95°C for 15 s and 59°C for 1 min. External quantitation standards were prepared from DNA isolated from ACH-2 cells in a background of HIV-1 negative human cellular DNA, calibrated to the Virology Quality Assurance (VQA, NIH Division of AIDS) cellular DNA quantitation standards. Cell counts were determined by qPCR using human genomic TERT (Applied Biosystems, cat\# 4403316). Copy number was determined by extrapolation against a 7-point standard curve (1--10,000 copies) performed in triplicate. Cell-associated HIV RNA copy number was determined using a reaction volume of 20 μL with 10 μL of 2x TaqMan® RNA to Ct 1 Step kit (Applied Biosystems, cat\# 4392656), 4 pmol of each primer, 4 pmol of probe, 0.5 μL reverse transcriptase, and 5 μL of RNA. Cycling conditions were 48°C for 20 min, 95°C for 10 min, then 60 cycles of 95°C for 15 s and 59°C for 1 min. External quantitation standards were prepared from RNA isolated from NL4--3 virus, calibrated to the Virology Quality Assurance (VQA, NIH Division of AIDS) HIV RNA quantitation standards. Cell counts were determined by qPCR using human RPLP0 (Applied Biosystems, cat\# 4310879E). Copy number was determined by extrapolation against a 7-point standard curve (1--10,000 copies) performed in triplicate.

### Phenotypic characterization of SLe^X+^ and CLA^+^ CD4^+^ T cells {#S26}

Cryopreserved PBMC were thawed, counted, examined for viability and rested overnight at 37°C and 5% CO~2~ in complete medium (RPMI supplemented with 10% FBS, 2 mM L-glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin). Cells were counted and plated for staining in 96-well V-bottom plates at 2--3 million cells per well. Stains for SLe^X^ stain and CLA analyses were performed in parallel. Cells were then stained for viability exclusion for 10 minutes at room temperature. The extracellular antibody cocktail mix containing either SLe^x^ or CLA was diluted in 1:1 Brilliant Stain Buffer Plus (BD Biosciences, cat\# 566385) and FACS buffer (PBS with 0.1% sodium azide and 1% BSA), added and incubated at room temperature in the dark for 20 minutes. Cells were then washed and permeabilized using the eBiosciences FoxP3 Transcription Factor buffer kit (Invitrogen, cat\# 00-5523-00) following the manufacturer's instructions. Intracellular antibody cocktail was incubated for one hour in the dark. Following intracellular stain, cells were washed and fixed with PBS with 1% paraformaldehyde, and stored at 4°C in the dark until acquisition. Data were collected on a BD FACSymphony A5 flow cytometer (BD Biosciences) and analyzed using FlowJo software (Tree Star). The following antibodies were used for staining: CD3-BUV805 (clone UCHT1, BD Biosciences, cat\# 565515), CD4-BB700 (clone SK3, BD Biosciences, cat\# 566392), CD8-BUV496 (clone RPA-T8, BD Biosciences, cat\# 564804), CD25-BUV737 (clone 2A3, BD Biosciences, cat\# 564385), CD38-BUV661 (clone HIT2, BD Biosciences, cat\# 565069), CD45RA-BUV563 (clone HI100, BD Biosciences, cat\# 565702), CD69-PE (clone FN50, BD Biosciences, cat\# 555531), CD127-BV480 (clone HIL-7RM21, BD Biosciences, cat\# 566101), CCR4-PE-CF594 (clone 1G1, BD Biosciences, cat\# 565391), CCR5-BV650 (clone 3A9, BD Biosciences, cat\# 564999), CCR6-BV421 (clone 11A9, BD Biosciences, cat\# 562515), CXCR4-PE Cy5 (clone 12G5, BD Biosciences, cat\# 555975), CXCR5-BB515 (clone RF8B2, BD Biosciences, cat\# 564624), HLA DR-BV605 (clone G46--6, BD Biosciences, cat\# 562845), Ki67-BUV395 (clone B56, BD Biosciences, cat\# 564071), SLe^X^ (CD15s)-AF647 (clone CSLEX1, BD Biosciences, cat\# 563526), CD14-BV510 (clone M5E2, Biolegend, cat\# 301842), CD19-BV510 (clone HIB19, Biolegend, cat\# 302242), CD27-BV570 (clone O323, Biolegend, cat\# 302825), CD95-BV711 (clone DX2, Biolegend, cat\# 305644), CLA-AF647 (clone HECA-452, Biolegend, cat\# 321309), CCR7-APC-Cy7 (clone G043H7, Biolegend, cat\# 353211), CXCR3-AF700 (clone G025H7, Biolegend, cat\# 353731) and PD-1-BV785 (clone EH12.2H7, Biolegend, cat\# 329930). The FoxP3-PE Cy7 (clone 236A/E7, cat\# 25-4777-42) antibody was purchased from eBioscience. The Invitrogen Live/Dead Fixable Aqua Dead Cell Stain Kit (Invitrogen, cat\# L34955) was used for viability exclusion.

### in vitro infection of unstimulated primary CD4^+^ T cells without CD44 Microbeads {#S27}

Isolated CD4^+^ T cells from three healthy donors were incubated in RPMI 1640 medium supplemented with 10% FBS, L-glutamine (2 mM), penicillin (50 U/ml), streptomycin (50 mg/ml), and 30 U/ml IL-2. Cells were then spinoculated with either IIIB or 89.6 (PBS was used as a control) at a concentration of 50 ng of p24 per 1 × 10^6^ cells for 2 h at 1,200 × g at 37°C. After spinoculation, all cells were returned to culture in the presence of 30 U/ml IL-2. Four days later, cells were stained with intracellular viral Gag p24 viral protein (PE-anti-p24 antibody; clone KC57, Beckman Coulter cat\# 6604665) and SLe^X^ (BD biosciences, cat\# 563526), or CLA (Biolegend, cat\#321309). A violet viability dye for flow cytometry (Invitrogen, cat\# L34955) was included to determine the cell viability. All samples were run on an LSR II flow cytometer and FACSDiva software. Data were analyzed with FlowJo.

### CLA depletion from primary CD4^+^ T cells {#S28}

Five million purified CD4^+^ T cells were incubated with anti-human/mouse CLA antibody (clone HECA-452, BioLegend, cat\#321309) at 25 μg/ml in 1X PBS supplemented with 0.5% BSA at 4°C for 10 min. Cells were washed twice and further incubated with 25 μl anti-rat kappa MicroBeads (Miltenyi Biotec, cat\# 130-047-401) for 15 min at 4°C. Cells were washed once and loaded onto pre-equilibrated LS columns (Miltenyi Biotec, cat\#130-042-401) according to manufacturer's instructions. After washing extensively, cells in the eluate fraction were pelleted and resuspended in RPMI 1640 medium supplemented with 10% FBS, L-glutamine (2 mM), penicillin (50 U/ml), streptomycin (50 mg/ml), and 30 U/ml IL-2.

### Infection of unstimulated primary CD4^+^ T cells using CD44 MicroBeads {#S29}

CLA-depleted CD4^+^ T cells from healthy donors were rested overnight in RPMI 1640 medium supplemented with 10% FBS, L-gluta-mine (2 mM), penicillin (50 U/ml), streptomycin (50 mg/ml), and 30 U/ml IL-2. 2 mL of CEMx174-grown HIV-1 DH12 (9,765,625 TCID50/ml) and 89.6 (5,710,972 TCID50/ml) were mixed with 100 μl of HIV Infectivity Enhancement Reagent (Miltenyi Biotec, cat\# 130-095-093) and incubated at 4°C for 30 min. 500 μl of the virus-MicroBead mixture were then added to approximately 300,000 unstimulated CD4^+^ T cells for 16 h in a 48 well culture plate. After overnight incubation, cells were washed once with 5 times volume of culture medium and incubated for additional 48 h at 37°C. Aliquots of virus exposed cells were taken from culture, washed with 1X PBS supplemented with 0.5% BSA and 0.1% sodium azide (FLOW buffer). Next, cells were stained with surface markers AF647-labeled anti-human/mouse CLA (clone HECA-452, BioLegend, cat\# 321309) and AF647-labeled anti-human SLe^X^ (CD15s)-AF647 (clone CSLEX1, BD Biosciences, cat\# 563526) in FLOW buffer for 30 min at room temperature protected from light. Cells were washed twice with 1 mL FLOW buffer and fixed using the Cytofix fixation buffer (BD BioSciences, cat\# 554714) at 4°C for 20 min. After cell fixation, cells were permeabilized using the Perm/Wash buffer (BD BioSciences, cat\# 554723) according to manufacturer's instructions before incubation with anti-p24 antibody (clone KC57, Beckman Coulter cat\# 6604665) for 30 min at room temperature. Cells were washed, resuspended in FLOW buffer and acquired on a BD LSR-II (18 color).

### Western blotting of glycosyltransferases and HIV p24 using H9 cell lysates {#S30}

HIV-infected and uninfected H9 cells were pelleted and resuspended in radioimmunoprecipitation assay (RIPA) buffer (25 mM Tris-HCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS) supplemented with protease inhibitor cocktail (Thermo Scientific, cat\# 87786). After centrifugation, the protein concentration in the cell lysates was determined using Bicinchoninic acid (BCA) assay (Thermo Scientific, cat\# 23235). 1 μg of total protein lysates were resolved on a 4%--12% Bis-Tris gel at 200 V for 30 min. Resolved proteins were transferred to nitrocellulose membranes, blocked and probed with the following primary antibodies: human Fucosyltransferase 7/FUT7 antibody, (clone 795116, R&D Systems, cat\# MAB64091), B4GALT5 antibody (Novus, cat\# NBP2--14882), GAPDH antibody (clone 14C10, Cell Signaling Technology, cat\# 2118), anti-p24 antibody (clone KC57, Beckman Coulter cat\# 6604665), and FUT6 Antibody (Thermo Fisher, cat\# PA5--96261). After two washes in 1X TBS supplemented with 0.05% Tween 20, membranes were incubated with HRP-conjugated secondary antibody: Peroxidase AffiniPure Donkey Anti-Rabbit IgG (H+L) antibody (Jackson ImmunoResearch, cat\# 711-035-152). Bound HRP-conjugated antibodies were revealed with SuperSignal West Pico PLUS chemiluminescent substrate (Thermo Scientific, cat\# 34580).

### in vitro stimulation of primary CD4^+^ T cells {#S31}

Isolated CD4^+^ T cells from three healthy donors were incubated in RPMI 1640 medium supplemented with 10% FBS, L-glutamine (2 mM), penicillin (50 U/ml), and streptomycin (50 mg/ml). Cells were then treated with αCD3/αCD28 activating beads (at a concentration of 1 bead/cell, GIBCO cat\#11131D), TNF-α (10 ng/mL, Peprotech, cat\# 300--01A), IL-2 (30 IU/ml, Peprotech, cat\#200--20), IL-2+αCD3/αCD28, IL-2+TNF-α, or PBS as a control. Four days later, cells were stained with SLe^X^ (BD biosciences, cat\#563526), or CLA (Biolegend, cat\#321309). A violet viability dye for flow cytometry (Invitrogen, cat\# L34955) was included to determine the cell viability. All samples were run on an LSR II flow cytometer and FACSDiva software. Data were analyzed with FlowJo.

### CyTOF analysis of CD4^+^ T cells isolated from HIV-infected ART-suppressed individuals {#S32}

CD4^+^ T cells were freshly isolated from the PBMCs of nine HIV-infected ART-suppressed individuals using the Human EasySep Human CD4^+^ T Cell Isolation Kit (StemCell Technologies, cat\#17952). Cells were fixed and stained with 25 μM cisplatin (cis-Diammine-platinum(II) dichloride, crystalline) (Sigma-Aldrich, cat\# P4394--25MG) as a viability, washed, and then fixed with 2% PFA. To stain multiple samples at the same time, barcoding of cells was conducted using the Cell-ID 20-Plex Pd Barcoding Kit according to manufacturer's instructions (Fluidigm, cat\# 201060). Barcoded samples were combined and blocked for 15 min on ice using sera from mouse (Thermo Fisher, cat\# 501121171), rat (Thermo Fisher, cat\# 10710C), and human (AB serum, Sigma-Aldrich, cat\# H4522--20ML). Cells were then washed 2x with CyFACS buffer (metal contaminant-free PBS (Rockland, cat\# MB-008) supplemented with 0.1% bovine serum albumin and 0.1% sodium azide) and stained with a cocktail of metal isotope-conjugated antibodies ([Table S5](#SD1){ref-type="supplementary-material"}). Antibody staining was performed in a total volume of 100 μL for 45 min on ice and followed by 3 washes with CyFACS buffer. After 3 washes with CyFACS buffer, cells were fixed overnight at 4°C with 2% PFA (Electron Microscopy Sciences) in metal contaminant-free PBS (Rockland). The next day, cells were permeabilized by incubation for 30 min at 4°C with fix/perm buffer (eBioscience, cat\# 00-5523-00), and washed 2x with Permeabilization Buffer (eBioscience, cat\# 00-5523-00). Cells were then blocked for 15 min on ice with sera from mouse (Thermo Fisher, cat\# 501121171) and rat (Thermo Fisher, cat\#10710C). After 2x washes with Permeabilization Buffer (eBioscience, cat\# 00-5523-00), cells were stained for 45 min on ice with the Survivin antibody (R&D Systems, cat\# MAB886) ([Table S5](#SD1){ref-type="supplementary-material"}). After another round of washing with CyFACS, cells were incubated for 20 min at room temperature with 250 nM Cell-ID™ DNA Intercalator-Ir (Fluidigm, cat\# 201192A) in 2% PFA diluted in PBS. Prior to acquisition, cells were washed 2x with CyFACS, 1x with Maxpar® Cell Staining Buffer (Fluidigm, cat\# 201068), 1x with Maxpar® PBS (Fluidigm, cat\#201058), and 1x with Maxpar® Cell Acquisition Solution (Fluidigm, cat\# 201240). Cells were then resuspended to a concentration of 7 ×10^5^ / ml in EQ™ calibration beads (Fluidigm, cat\# 201078) diluted in Maxpar® Cell Acquisition Solution. Cells were acquired at a rate of 250--350 events / sec on a CyTOF2 instrument (Fluidigm) at the UCSF Flow Cytometry Core. Data were normalized with EQ™ calibration beads and analyzed with FlowJo

### RNA Sequencing {#S33}

The NEBNext Ultra RNA Library Prep Kit for Illumina (New England Biolabs, cat\# E7530S) was used to prepare the RNA sequencing libraries following the manufacturer's recommendations. Briefly, mRNA was enriched with Oligo d(T) beads. Enriched mRNAs were fragmented, and the first-strand and second-strand cDNA were then synthesized. cDNA fragments were end repaired and adenylated at 3^′^ends, and a universal adaptor was ligated to cDNA fragments, followed by index addition and library enrichment with limited cycle PCR. Sequencing libraries were validated using a DNA Chip on the Agilent 2100 Bioanalyzer (Agilent Technologies) and quantified by using Qubit 2.0 Fluorometer (Invitrogen) and quantitative PCR (Applied Biosystems). The sequencing libraries were multiplexed and clustered onto a flowcell. After clustering, the flowcell was loaded on the Illumina HiSeq 2500 instrument according to manufacturer's instructions. The samples were sequenced using a 2×50bp Paired Read (PR) configuration. Image analysis and base calling were conducted by the HiSeq Control Software (HCS) on the HiSeq 2500 instrument. Raw sequence data (.bcl files) generated from the Illumina HiSeq 2500 were converted into fastq files and de-multiplexed using the Illumina bcl2fastq v 1.8.4 program. The sequencing reactions were conducted at GENEWIZ, LLC.

### RNASeq Analysis {#S34}

RNA-seq data were aligned using *bowtie2* against the hg38 version of the human genome, and *RSEM* v1.2.12 software was used to estimate raw read counts and RPKM using Ensemble transcriptome information and *DESeq2* was used for raw count normalization and pairwise comparison between groups ([@R43]; [@R45]; [@R47]). Genes that changed at least 2 fold with FDR \< 5% were considered significant. Gene set enrichment analysis was done using QIAGEN's Ingenuity® Pathway Analysis software (IPA®, QIAGEN Redwood City, <https://digitalinsights.qiagen.com/>) the Benjamini-Hochberg procedure to estimate the false discovery rate (FDR) ([@R4]). Select functions that passed p \< 10^−7^ and pathways that passed p \< 0.05 significance threshold and had at least ten significant genes were reported. Predicted activation Z-score calculated by IPA based on the known effect and direction of change of membership genes.

QUANTIFICATION AND STATISTICAL ANALYSIS {#S35}
---------------------------------------

Data were analyzed using Prism 6.0 and 7.0 (GraphPad Software). Mann-Whitney U-tests, Wilcoxson rank tests, paired t tests, Spearman's rank correlation coefficient tests, and Friedman tests were used. Statistical comparisons in [Figures 1A](#F1){ref-type="fig"}--[1D](#F1){ref-type="fig"} (n = 7) were performed using two-tailed non-parametric Wilcoxon rank tests. Statistical comparisons in [Figures 1E](#F1){ref-type="fig"} and [1F](#F1){ref-type="fig"} (n = 6 for HIV-negative controls; 7 for HIV-infected ART-suppressed individuals, and 8 for HIV-infected viremic individuals) were performed using Mann-Whitney U-tests. All infection experiments in [Figure 2](#F2){ref-type="fig"} were conducted 3 times to ensure reproducibility and Paired t tests were used for statistical analysis. Friedman test (paired, non-parametric) was used for analysis in [Figures 3](#F3){ref-type="fig"} and [4](#F4){ref-type="fig"} (n = 6 for HIV-negative controls; 7 for HIV-infected ART-suppressed individuals, and 8 for HIV-infected viremic individuals). Wilcoxon signed-rank test was used for statistical analysis in [Figure 5](#F5){ref-type="fig"} (n = 9). Statistical comparisons in [Figure 6](#F6){ref-type="fig"} (n = 4) were performed using paired t tests. False discovery rate (FDR) was calculated using the Benjamin-Hochberg procedure. For [Figures 1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"}, [4](#F4){ref-type="fig"}, and [5](#F5){ref-type="fig"}, Differences were considered statistically significant when the p value was less than 0.05, with \* p \< 0.05, \*\* p \< 0.01, \*\*\* p \< 0.001, \*\*\*\* p \< 0.0001. FDR \< 5% and 2 at least fold was considered significant in [Figure 6](#F6){ref-type="fig"}. PCA and hierarchical clustering were performed using R-Studio.
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![CD4^+^ T Cell-Surface Fucosylation and SLe^X^ Expression Associate with Persistent HIV Transcription In Vivo\
(A--D) CD4^+^ T cells from HIV-infected ART-suppressed individuals were sorted based on levels of cell-surface fucosylation, SLe^X^, or CLA expression (lowest 5%, medium, and highest 5%); levels of HIV DNA and cell-associated HIV RNA (total elongated transcripts) were measured by qPCR. The ratio of cell-associated HIV RNA to HIV DNA was calculated.\
(A and B) Cells with high fucose, either total/core (A) or branched (B), exhibited higher levels of cell-associated HIV RNA compared with cells with low fucose, despite a less dramatic difference in levels of HIV DNA.\
(C and D) Cells with high levels of SLe^X^ (C) or CLA (D) exhibited higher levels of cell-associated HIV RNA compared with cells with low levels of SLe^X^ or CLA, despite similar levels of HIV DNA *in vivo*. Furthermore, cells with SLe^X-Hi^ exhibited higher ratio of cell-associated HIV RNA to HIV DNA compared with cells with SLe^X-Low^ (C). Lines and error bars represent the median and IQR. All statistical comparisons were performed using two-tailed non-parametric Wilcoxon rank tests. \*p \< 0.05.\
(E and F) Percentage of SLe^X^ (E) and CLA (F) within total and memory CD4^+^ T cells of HIV-negative, HIV-infected ART-suppressed, and HIV-infected viremic individuals.\
Lines and error bars represent the median and IQR. Statistical comparisons were performed using two-tailed non-parametric Mann-Whitney U tests. n = 6 for HIV-negative controls; 7 for HIV-infected ART-suppressed individuals, and 8 for HIV-infected viremic individuals. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001.](nihms-1617875-f0002){#F1}

![HIV Infection Induces the Expression of SLe^X^ and CLA on the Surface of Primary CD4^+^ T Cells In Vitro\
(A) Isolated CD4^+^ T cells from three HIV-negative donors were infected with either the HIV 89.6 virus (at a multiplicity of infection \[MOI\] of 6) or the HIV DH12 virus (at MOI of 10) by spinoculation in the presence of CD44 MicroBeads. Four days later, intracellular p24 expression and cell-surface expression of SLe^X^ were determined by flow cytometry.\
(B) Isolated CD4^+^ T cells from three HIV-negative donors were depleted of CLA^+^ cells. CLA-depleted cells were infected with either HIV 89.6 or HIV DH12 by spinoculation in the presence of CD44 MicroBeads. Four days later, intracellular p24 expression and cell-surface expression of CLA were determined by flow cytometry. (A and B) Top panels show the percentage of SLe^X^ or CLA on total, p24+, and p24-negative cells, as well as controls (cells treated with CD44 MicroBeads alone), for each HIV strain. Bottom panels are representative flow cytometry plots of dually stained CD4^+^ T cells for HIV p24 protein and SLe^X^ or CLA. Mean and standard error of the mean (SEM) are presented. Paired t tests were used for statistical analysis.\
(C) H9 cell line was infected with either HIV 89.6 (MOI of 6) or NL4--3 (MOI of 0.1) in the presence of CD44 MicroBeads. Protein expression of several glycosyltransferases involved in SLe^X^ and CLA production (FUT6, FUT7, and B4GALT5), as well as HIV p24, was measured by western blotting. Diagrams show locations of glycosidic bonds catalyzed by indicated glycosyltransferases.](nihms-1617875-f0003){#F2}

![SLe^X^ Expression Is Enriched on T~CM~ and Naive CD4^+^ and Associates with Higher Activation Status\
(A) Memory subset distribution of SLe^X+^ cells in HIV^−^, HIV^+^ ART-suppressed, and HIV^+^ viremic donors.\
(B) Frequency of SLe^X+^ cells within each memory CD4^+^ T cell subset in the analyzed groups. Subsets were defined as T~N~ (naive; CD45RA^+^ CD27^+^ CCR7^+^ CD95^−^), T~SCM~ (stem cell memory; CD45RA^+^ CD27^+^ CCR7^+^ CD95^+^), T~EMRA~ (effector memory RA^+^; CD45RA^+^ CD27^−^), T~EM~ (effector memory; CD45RA^−^ CD27^−^CCR7^−^), T~CM~ (central memory; CD45RA^−^ CD27^+^ CCR7^+^), and T~TM~ (transitional memory; CD45RA^−^ CD27^+^ CCR7^−^). Lines and error bars represent the median and IQR. All statistical comparisons were performed using two-tailed Wilcoxon rank tests.\
(C) Heatmaps showing the statistical difference in the frequency of all measured phenotypic markers in SLe^X+^ and SLe^X−^ cells.\
All data were analyzed using a Friedman test (paired, non-parametric). n = 6 for HIV^−^, 7 for HIV^+^ ART-suppressed individuals, and 8 for HIV^+^ viremic individuals. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001.](nihms-1617875-f0004){#F3}

![CLA^high^ CD4^+^ T Cells Cluster Distinctly from CLA^low^ and CLA^negative^ CD4^+^ T Cells\
(A) Left, heatmap showing the frequency of all measured phenotypic markers in CLA^high^, CLA^low^, and CLA^−^ cells. Right, PCA showing the distribution of CLA^high^, CLA^low^, and CLA^−^ cells subsets.\
(B) Memory subset distribution of CLA^high^ cells in HIV^−^, HIV^+^ ART-treated, and HIV^+^ viremic individuals.\
(C) Frequency of CLA^high^ cells within each memory CD4^+^ T cell subset in the analyzed groups. Lines and error bars represent the median and IQR. All statistical comparisons were performed using two-tailed Wilcoxon rank tests.\
(D) Heatmaps showing the statistical difference in the frequency of all measured phenotypic markers CLA^high^, CLA^low^, and CLA^−^ cells.\
All data were analyzed using a Friedman test (paired, non-parametric). n = 6 for HIV^−^, 7 for HIV^+^ ART-suppressed individuals, and 8 for HIV^+^ viremic individuals. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001.](nihms-1617875-f0005){#F4}

![SLe^X+^ and SLe^X−^ CD4^+^ T Cells Have Differential Levels of Host Factors Known to Be Enriched in HIV-Infected Cells during ART\
CyTOF analysis of CD4^+^ T cells freshly isolated from PBMCs of nine HIV-infected ART-suppressed individuals. Cells were stained for SLe^X^, PD-1, TIGIT, CTLA-4, CD30, CCR6, or Survivin.\
(A) Percentage of SLe^X+^ and SLe^X−^ CD4^+^ T cells expressing each of the indicated factors.\
(B) Mean signal intensity of SLe^X^ on the surface of cells expressing or not each of the indicated factors.\
Median and IQR are presented, and p values were calculated using Wilcoxon signed-rank test. \*\*p \< 0.01.](nihms-1617875-f0006){#F5}

![SLe^X+^ CD4^+^ T Cells Are Enriched for Pathways Involved in T Cell Extravasation and HIV Transcription\
(A) Relative expression of GCNT1 and FUT7 genes in SLe^X-Hi^ and SLe^X-Low^ CD4^+^ T cells isolated from four HIV^+^ ART-suppressed individuals. Mean and SEM are presented, and p values were calculated using paired t tests. FDR was calculated using the Benjamin-Hochberg procedure.\
(B and C) List of significantly enriched pathways (B) and functions (C) found by IPA among 1,086 genes significantly different (FDR \< 5%, at least 2-fold) between SLe^X-Hi^ and SLe^X-Low^ CD4^+^ T cells. N, number of genes significantly changed in the pathway; % up, percentage of genes expressed at higher levels in SLe^X-Hi^ compared with SLe^X-Low^ CD4^+^ T cells; Z, activation *Z* score of the pathway or function predicted by IPA based on the direction of changes and contribution of membership genes; Positive, activated; negative, inhibited in SLe^X-Hi^.\
(D and E) Genes differentially expressed (FDR \< 5%) in SLe^X-Hi^ compared with SLe^X-Low^ CD4^+^ T cells that belong to (D) leukocyte extravasation signaling or (E) NF-κB signaling. Red dots are genes expressed at higher levels in SLe^X-Hi^ compared with SLe^X-Low^ CD4^+^ T cells, whereas blue dots are genes expressed at lower levels in SLe^X-Hi^ compared with SLe^X-Low^ CD4^+^ T cells.](nihms-1617875-f0007){#F6}

###### 

KEY RESOURCES TABLE

  REAGENT or RESOURCESOURCE                                                                               SOURCE                                                                                                                             IDENTIFIER
  ------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------- --------------------------------------
  Antibodies                                                                                                                                                                                                                                 
  CD3-BUV805 clone UCHT1                                                                                  BD Biosciences                                                                                                                     cat\# 565515; RRID:AB_2739277
  CD4-BB700 clone SK3                                                                                     BD Biosciences                                                                                                                     cat\# 566392; RRID:AB_2744421
  CD8-BUV496 clone RPA-T8                                                                                 BD Biosciences                                                                                                                     cat\# 564804; RRID:AB_2744460
  CD14-BV510 clone M5E2                                                                                   Biolegend                                                                                                                          cat\# 301842; RRID:AB_2561946
  CD19-BV510cloneHIB19                                                                                    Biolegend                                                                                                                          cat\# 302242; RRID:AB_2561668
  CD25-BUV737 clone 2A3                                                                                   BD Biosciences                                                                                                                     cat\# 564385; RRID:AB_2744342
  CD27-BV570 clone O323                                                                                   Biolegend                                                                                                                          cat\# 302825; RRID:AB_11149686
  CD38-BUV661 clone HIT2                                                                                  BD Biosciences                                                                                                                     cat\# 565069; RRID:AB_2744377
  CD45RA-BUV563 clone HI100                                                                               BD Biosciences                                                                                                                     cat\# 565702; RRID:AB_2744407
  CD69-PE clone FN50                                                                                      BD Biosciences                                                                                                                     cat\# 555531; RRID:AB_395916
  CD95-BV711 clone DX2                                                                                    Biolegend                                                                                                                          cat\# 305644; RRID:AB_2632623
  CD127-BV480 clone HIL-7R-M21                                                                            BD Biosciences                                                                                                                     cat\# 566101
  CCR4-PE-CF594 clone 1G1                                                                                 BD Biosciences                                                                                                                     cat\# 565391; RRID:AB_2739215
  CCR5-BV650 clone 3A9                                                                                    BD Biosciences                                                                                                                     cat\# 564999; RRID:AB_2739037
  CCR6-BV421 clone 11A9                                                                                   BD Biosciences                                                                                                                     cat\# 562515; RRID:AB_11154229
  CCR7-APC-Cy7 clone G043H7                                                                               Biolegend                                                                                                                          cat\# 353211; RRID:AB_10915272
  CXCR3-AF700 clone G025H7                                                                                Biolegend                                                                                                                          cat\# 353731; RRID:AB_2563532
  CXCR4-PE Cy5 clone 12G5                                                                                 BD Biosciences                                                                                                                     cat\# 555975; RRID:AB_396268
  CXCR5-BB515 clone RF8B2                                                                                 BD Biosciences                                                                                                                     cat\# 564624; RRID:AB_2738871
  HLA DR-BV605 clone G46-6                                                                                BD Biosciences                                                                                                                     cat\# 562845; RRID:AB_2744478
  FoxP3-PE Cy7 clone 236A/E7                                                                              eBioscience                                                                                                                        cat\# 25-4777-42; RRID:AB_2573450)
  Ki67-BUV395 clone B56BDBiosciencescat\# 56                                                              BD Biosciences                                                                                                                     cat\# 564071; RRID:AB_2738577
  PD-1-BV785 clone EH12.2H7                                                                               Biolegend                                                                                                                          cat\# 329930; RRID:AB_2563443
  SLe^X^ (CD15s)-AF647 clone CSLEX1                                                                       BD Biosciences                                                                                                                     cat\# 563526; RRID:AB_2738258
  CLA-AF647 clone HECA-452                                                                                Biolegend                                                                                                                          cat\# 321309; RRID:AB_2563661
  CD19-142Nd clone HIB19                                                                                  Fluidigm                                                                                                                           cat\# 3142001; RRID: AB_2651155
  CD8-146Nd clone RPAT8                                                                                   Fluidigm                                                                                                                           cat\# 3146001B; RRID: AB_2687641
  CD62L-153Eu clone DREG56                                                                                Fluidigm                                                                                                                           cat\# 3153004B; RRID: AB_2810245
  TIGIT-154Sm clone MBSA43                                                                                Fluidigm                                                                                                                           cat\# 3154016B; RRID: NA
  CCR7-159Tb clone G043H7                                                                                 Fluidigm                                                                                                                           cat\# 3159003A; RRID: AB_2714155
  CD27-167Er clone L128                                                                                   Fluidigm                                                                                                                           cat\# 3167006B; RRID: AB_2811093
  CD45RA-169Tm clone HI100                                                                                Fluidigm                                                                                                                           cat\# 3169008B; RRID: NA
  CD3-170Er clone UCHT1                                                                                   Fluidigm                                                                                                                           cat\# 3170001B; RRID: AB_2811085
  CD4-174Yb clone SK3                                                                                     Fluidigm                                                                                                                           cat\# 3174004B; RRID: AB_2687862
  Human Survivin Antibody clone 91630                                                                     R&D Systems                                                                                                                        cat\# MAB886, RRID:AB_2243438
  HIV-1 core antigen-FITC, clone KC57                                                                     Beckman Coulter                                                                                                                    cat\# 6604665, RRID:AB_1575987
  Human Fucosyltransferase 7/FUT7 Antibody clone 795116                                                   R&D Systems                                                                                                                        cat\# MAB64091
  B4GALT5 polyclonal antibody                                                                             Novus                                                                                                                              cat\# NBP2-14882
  GAPDH antibody, clone 14C10                                                                             Cell Signaling Technology                                                                                                          cat\# 2118, RRID:AB_561053
  Peroxidase AffiniPure Donkey Anti-Rabbit IgG (H+L)                                                      Jackson ImmunoResearch                                                                                                             cat\# 711--035-152, RRID:AB_10015282
  FUT6 Polyclonal Antibody                                                                                Thermo Fisher                                                                                                                      cat\# PA5-96261, RRID:AB_2808063
  Bacterial and Virus Strains                                                                                                                                                                                                                
  dfHIV                                                                                                   Generously provided to us by Dr. Leonard Chavez at Vitalant Research Institute                                                     N/A
  HIV-1 1MB                                                                                               The Virus and Reservoirs Core at Penn Center for AIDS Research                                                                     N/A
  HIV-1 89.6                                                                                              The Virus and Reservoirs Core at Penn Center for AIDS Research                                                                     N/A
  HIV-1 DH12                                                                                              The Virus and Reservoirs Core at Penn Center for AIDS Research                                                                     N/A
  HIV-1 NL43                                                                                              The Virus and Reservoirs Core at Penn Center for AIDS Research                                                                     N/A
  Biological Samples                                                                                                                                                                                                                         
  CD4^+^ T cells isolated from PBMC of HIV-infected antiretroviral therapy (ART)-suppressed individuals   External Quality Assurance Program Oversight Laboratory (EQAPOL)- Duke Human Vaccine Institute's Immunology and Virology Quality   N/A
  CD4^+^ T cells isolated from PBMC of HIV-infected ART-suppressed individuals                            The Wistar Institute and Philadelphia FIGHT                                                                                        N/A
  PBMCs from HIV-infected viremic and ART-treated individuals                                             INER-CIENI (Mexico)                                                                                                                N/A
  PBMC from healthy individuals                                                                           University of Pennsylvania Human Immunology Core                                                                                   N/A
  Normal mouse serum                                                                                      Thermo Fisher                                                                                                                      cat\# 501121171
  Normal rat serum                                                                                        Thermo Fisher                                                                                                                      cat\# 10710C
  Human serum                                                                                             Sigma-Aldrich                                                                                                                      cat\# H4522-20ML
  Chemicals, Peptides, and Recombinant Proteins                                                                                                                                                                                              
  RPMI1640 medium                                                                                         Corning                                                                                                                            cat\# 10-040-CM
  Penicillin-Streptomycin                                                                                 GIBCO                                                                                                                              cat\# 15140163
  Fetal Bovine Serum                                                                                      GIBCO                                                                                                                              cat\# 10437028
  Recombinant Human IL-2                                                                                  Prepotech                                                                                                                          cat\# 200-20
  Recombinant Human TNF-α                                                                                 Prepotech                                                                                                                          cat\# 300-01A
  cis-Diammineplatinum(II) dichloride                                                                     Sigma-Aldrich                                                                                                                      cat\# P4394-25MG
  AOL-biotin conjugated                                                                                   TCI America                                                                                                                        cat\# A26591 ML
  APC Streptavidin                                                                                        Biolegend                                                                                                                          cat\# 405207
  Ulex Europaeus Agglutinin I (UEA I), Fluorescein                                                        Vector Labs                                                                                                                        cat\# FL-1061-2
  Critical Commercial Assays                                                                                                                                                                                                                 
  TaqMan Universal Master Mix II, with UNG                                                                Applied Biosystems                                                                                                                 cat\# 4440038
  TaqMan Copy Number Reference Assay, human, TERT                                                         Applied Biosystems                                                                                                                 cat\# 4403316
  TaqMan RNA-to-CT 1-Step Kit                                                                             Applied Biosystems                                                                                                                 cat\# 4392656
  Human RPLP0 (Large Ribosomal Protein) Endogenous Control                                                Applied Biosystems                                                                                                                 cat\# 4310879E
  Brilliant Stain Buffer Plus                                                                             BD BioSciences                                                                                                                     cat\# 566385
  Fixation/Permeabilization Solution Kit                                                                  BD BioSciences                                                                                                                     cat\# 554714
  Perm/Wash Buffer                                                                                        BD BioSciences                                                                                                                     cat\# 554723
  Blotting-Grade Blocker                                                                                  BIO-RAD                                                                                                                            cat\# 1706404
  Falcon 48-well Clear Flat Bottom TC-treated Cell Culture Plate                                          Corning                                                                                                                            cat\# 353230
  Foxp3/Transcription Factor Staining Buffer Set                                                          eBioscience                                                                                                                        cat\# 00-5523-00
  Cell-ID 20-Plex Pd Barcoding Kit                                                                        Fluidigm                                                                                                                           cat\# 201060
  CyFACS buffer                                                                                           Fluidigm                                                                                                                           cat\# MB-008
  Cell-IDTM DNA Intercalator-Ir                                                                           Fluidigm                                                                                                                           cat\# 201192A
  Maxpar cell staining buffer                                                                             Fluidigm                                                                                                                           cat\# 201068
  Maxpar PBS                                                                                              Fluidigm                                                                                                                           cat\# 201058
  Maxpar Cell Acquisition Solution                                                                        Fluidigm                                                                                                                           cat\# 201240
  EQTM calibration beads                                                                                  Fluidigm                                                                                                                           cat\# 201078
  Cy®3 Mono 5-pack                                                                                        GE Healthcare                                                                                                                      cat\# GEPA23001
  Dynabeads Human T-Activator CD3/CD28 for T Cell Expansion and Activation                                GIBCO                                                                                                                              cat\# 11131D
  eBioscience Foxp3 / Transcription Factor Staining Buffer Se                                             Invitrogen                                                                                                                         cat\# 00-5523-00
  LIVE/DEAD Fixable Violet Dead Cell Stain Kit, for 405 nm excitation                                     Invitrogen                                                                                                                         cat\# L34955
  ProteoExtract Subcellular Proteome Extraction Kit                                                       Merck                                                                                                                              cat\# 539790
  DEAE-dextran                                                                                            MilliporeSigma                                                                                                                     cat\# D-9885
  Anti-rat kappa MicroBeads                                                                               Miltenyi Biotec                                                                                                                    cat\# 130-047-401
  LS columns                                                                                              Miltenyi Biotec                                                                                                                    cat\# 130-042-401
  QuadroMACS Separator                                                                                    Miltenyi Biotec                                                                                                                    cat\# 130-090-976
  MACS MultiStand                                                                                         Miltenyi Biotec                                                                                                                    cat\# 130-042-303
  HIV Infectivity Enhancement Reagent                                                                     Miltenyi Biotec                                                                                                                    cat\# 130-095-093
  NEBNext Ultra RNA Library Prep Kit for Illumina                                                         New England Biolabs                                                                                                                cat\# E7530S
  Bright-Glo Luciferase Assay System                                                                      Promega                                                                                                                            cat\# E2610
  AllPrep DNA/RNA/miRNA Universal Kit                                                                     QIAGEN                                                                                                                             cat\# 80224
  RNase-Free DNase Set                                                                                    QIAGEN                                                                                                                             cat\# 79254
  Bovine Serum Albumin                                                                                    R&D Systems                                                                                                                        cat\# 5217
  CyFACS buffer                                                                                           Rockland                                                                                                                           cat\# MB-008
  EasySep Human CD4~+~ T Cell Isolation Kit                                                               Stem Cell                                                                                                                          cat\# 17952
  NuPAGE 4-12% Bis-Tris Protein Gels, 1.0 mm, 12-well                                                     Thermo Fisher                                                                                                                      cat\# NP0322BOX
  NuPAGE Sample Reducing Agent (10X)                                                                      Thermo Fisher                                                                                                                      cat\# NP0004
  NuPAGE LDS Sample Buffer (4X)                                                                           Thermo Fisher                                                                                                                      cat\# NP0007
  iBlot 2 Transfer Stacks, nitrocellulose, mini                                                           Thermo Fisher                                                                                                                      cat\# IB23002
  Novex Sharp Pre-stained Protein Standard                                                                Thermo Fisher                                                                                                                      cat\# LC5800
  SuperSignal West Pico PLUS Chemiluminescent Substrate                                                   Thermo Fisher                                                                                                                      cat\# 34580
  RIPA Lysis and Extraction Buffer                                                                        Thermo Fisher                                                                                                                      cat\# 89900
  Bicinchoninic acid (BCA) assay                                                                          Thermo Fisher                                                                                                                      cat\# 23235
  Halt Protease Inhibitor Cocktail (100X)                                                                 Thermo Fisher                                                                                                                      cat\# 87786
  CL-XPosure Film, 8 × 10 in. (20 × 25 cm)                                                                Thermo Fisher                                                                                                                      cat\# 34091
  Deposited Data                                                                                                                                                                                                                             
  RNaseq data                                                                                             Deposited to GEO (<https://www.ncbi.nlm.nih.gov/geo/>)                                                                             Accession number GSE151453
  Experimental Models: Cell Lines                                                                                                                                                                                                            
  ACH-2                                                                                                   NIH AIDS Reagent Program                                                                                                           cat\# 349
  H9                                                                                                      NIH AIDS Reagent Program                                                                                                           cat\# 87
  TZM-bl                                                                                                  NIH AIDS Reagent Program                                                                                                           cat\# 8129
  Oligonucleotides                                                                                                                                                                                                                           
  F522-43 (5′ GCC TCA ATA AAG CTT GCC TTGA3′                                                              IDT                                                                                                                                ([@R40])
  R626-43 (5′ GGG CGC CAC TGC TAG AGA3′                                                                   IDT                                                                                                                                ([@R40])
  FAM-BQ probe (5′ CCA GAG TCA CAC AAC AGA CGG GCA CA 3′                                                  IDT                                                                                                                                ([@R40])
  Software and Algorithms                                                                                                                                                                                                                    
  FlowJo software (Tree Star).                                                                            <https://www.flowjo.com/>                                                                                                          RRID:SCR_008520
  *bowtie2*                                                                                               <http://bowtie-bio.sourceforge.net/index.shtml>                                                                                    RRID:SCR_005476
  *RSEM* v1.2.12                                                                                          <http://deweylab.biostat.wisc.edu/rsem/>                                                                                           RRID:SCR_013027
  *DESeq2*                                                                                                <https://bioconductor.org/packages/release/bioc/html/DESeq2.html>                                                                  RRID:SCR_015687
  QIAGEN's Ingenuity® Pathway Analysis software                                                           <https://digitalinsights.qiagen.com/>                                                                                              RRID:SCR_008653
  Prism 6.0 and 7.0                                                                                       <http://www.graphpad.com/>                                                                                                         RRID:SCR_002798
  Rstudio                                                                                                 <https://rstudio.com/>                                                                                                             RRID:SCR_000432
  FACSDiva software                                                                                       <http://www.bdbiosciences.com/instruments/software/facsdiva/index.jsp>                                                             RRID:SCR_001456
  HiSeq control software                                                                                  <https://www.illumina.com/systems/sequencing-platforms/hiseq-2500/products-services/hiseq-control-software.html>                   N/A

###### Highlights

-   Persistent HIV transcription modulates the glycosylation of infected cells

-   Cells actively transcribing HIV harbor high levels of fucosylated carbohydrates

-   HIV transcription induces the fucosylated extravasation mediator, Sialyl-Lewis^X^

-   Cells with high Sialyl-Lewis^X^ are enriched with pathways involved in trafficking
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